International Urogynecology Journal

, Volume 1, Issue 2, pp 74–79 | Cite as

Stress urinary incontinence in postmenopausal women treated with oral estrogen (estriol) and an alpha-adrenoceptor-stimulating agent (phenylpropanolamine): A randomized double-blind placebo-controlled study

  • S. Walter
  • B. Kjærgaard
  • G. Lose
  • J. T. Andersen
  • L. Heisterberg
  • H. Jakobsen
  • P. Klarskov
  • K. Møller-Hansen
  • M. Lindskog
Original Article


Twenty-eight postmenopausal women with objectively verified stress incontinence completed a randomized double-blind placebo-controlled study. After an initial 4 weeks of placebo treatment the patients received either oral estriol (E3) (4mg daily) or oral phenylpropanolamine (PPA) (50 mg b.i.d.) alone for 4 weeks, followed by another 4 weeks of treatment with the two active drugs in combination.

Subjectively, 14 of 15 patients preferred PPA to placebo (P<0.001), 9 of 12 patients preferred E3 to placebo (P=0.011), and 10 of 14 patients preferred E3 + PPA to E3 (P=0.006). Two patients became continent on PPA, 2 on E3, and 12 of 28 patients on combined treatment. PPA gave a significant decrease in urine loss when compared with placebo (P=0.023), and the combined treatment of PPA + E3 also gave a reduction in urine loss when compared with placebo (P=0.022). It is concluded that estriol 4mg daily and PPA 50 mg b.i.d. are effective in the treatment of stress urinary incontinence in postmenopausal women. The enhanced effect of combined treatment is moderate and of questionable importance.


Stress incontinence Estriol Phenylpropanolamine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Diokno AC, Taub M. Ephedrine in treatment of urinary incontinence.Urology 1975 5:624–625Google Scholar
  2. 2.
    Ek A. Innervation and receptor funtions of the human urethra [Thesis]. Lund, Sweden;Studenterlitteratur, 1977Google Scholar
  3. 3.
    Ek A, Andersson K-E, Gullberg B, Ulmsten U. The effect of longterm treatment with norephedrine on stress incontinence and urethral closure pressure profile.Scand J Urol Nephrol 1978; 12:105–110Google Scholar
  4. 4.
    Ek A, Andersson K-E, Gullberg B, Ulmsten U. Effect of oestradiol treatment on female stress incontinence.Zentralbl Gynakol 1980; 102:839–844Google Scholar
  5. 5.
    Schreiter F, Fuchs P, Stockamp K. Estrogenic sensitivity of alpha-receptors in the urethra musculature.Urol Int 1976; 31:13–19Google Scholar
  6. 6.
    Abrams P, Blaivas JG, Stanton SL, Andersen JT. The standardisation of terminology of lower urinary tract function.Scand J Urol Nephrol 1988; suppl 114:5–19Google Scholar
  7. 7.
    Lönnerholm G, Grahnén A, Lindström B. Steady-state kinetics of sustained-released phenylpropanolamine.Int J Clin Pharmocol Ther Toxicol 1984; 22:39–41Google Scholar
  8. 8.
    Novak S. Gynecologic and obstetric pathology, 7th edn. Philadelphia: WB Saunders, 1974:641–642Google Scholar
  9. 9.
    Iosif S, Batra S, Ek A, Åstedt B. Oestrogen receptors in the human female lower urinary tract.Am J Obstet Gynecol 1981; 141:817–820Google Scholar
  10. 10.
    Nergårdh A, Boréus LD. Autonomic receptor function in the lower urinary tract of man and cat.Scand J Urol Nephrol 1972; 6:32–36Google Scholar
  11. 11.
    Walter S, Wolf H, Barlebo H, Jensen HK. Urinary incontinence in postmenopausal women treated with estrogens. A doubleblind clinical trial.Urol Int 1978; 33:135–143Google Scholar
  12. 12.
    Wilson PD, Faragher B, Butler B, Bullock D, Robinson EL, Brown ADG. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women.Br J Obstet Gynaecol 1987; 94:568–574Google Scholar
  13. 13.
    Beisland HO, Fossberg E, Moer A, Sander S. Urethral sphinteric insufficiency in postmenopausal females: Treatment with phenylpropanolamine and estrol separately and in combination.Urol Int 1984; 39:211–216Google Scholar
  14. 14.
    Hodgson BJ, Dumas S, Bolling DR, Heesek CM. Effect of estrogen on sensitivity of rabbit bladder and urethra to phenylephrine.Invest Urol 1978; 16:67–69Google Scholar
  15. 15.
    Callahan SM, Creed KE. The effects of oestrogens on spontaneous activity and response to phenylephrine of the mammalian urethra.J. Phusiol 1985; 358–46Google Scholar
  16. 16.
    Kinn A-C, Lindskog M. Estrogens and phenylpropanolamine in combination for stress urinary incontinence in postmenopausal women.Urol 1988; 23:273–280Google Scholar
  17. 17.
    Caine M, Raz S. The role of female hormones in stress incontinence. Proceedings of the 16th congress of the International Society of Urologists, Amsterdam, 1973Google Scholar
  18. 18.
    Eckerling B, Coldman JA, Israel PT. Conservative treatment of uterovaginal prolapse and stress urinary incontinence.Int. Surg 1972; 57:221–222Google Scholar
  19. 19.
    Faber P, Heidenreich J. Treatment of stress incontinence with estrogens in postmenopausal women.Urol Int 1977; 32:221–223Google Scholar
  20. 20.
    Punnonen R, Kikku P, Kiukko P, Rauramo L. Conservative treatment of urinary incontinence in women with special reference to the use of oestrogens.Maturitas 1981; 3:309–313Google Scholar
  21. 21.
    Kiesswetter H, Hennrich F, Englisch M. Clinical and urodynamic assessment of pharmacologic therapy of stress incontinence.Urol Int 1983; 38:58–63Google Scholar
  22. 22.
    Liebson I, Bigelow G, Griffiths RR, Funderburk FR. Phenylpropanolamine: Effects on subjective and cardiovascular variables at recommended over-the-counter dose levels.J Clin Pharmacol 1987; 27:685–693Google Scholar

Copyright information

© The International Urogynecology Journal 1990

Authors and Affiliations

  • S. Walter
    • 1
  • B. Kjærgaard
    • 1
  • G. Lose
    • 2
  • J. T. Andersen
    • 2
  • L. Heisterberg
    • 3
  • H. Jakobsen
    • 4
  • P. Klarskov
    • 4
  • K. Møller-Hansen
    • 5
  • M. Lindskog
    • 6
  1. 1.Department of UrologyAalborg HospitalAalborg
  2. 2.Department of UrologyRigshospitaletDenmark
  3. 3.Department of GynecologyBispebjerg HospitalDenmark
  4. 4.Department of UrologyHerlev HospitalDenmark
  5. 5.Department of PathologyBispebjerg HospitalDenmark
  6. 6.Department of Clinical ResearchPharmacia LEO Therapeutics ABSweden

Personalised recommendations